Schweinfurthin a selectively inhibits proliferation and rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1234-1243

  Turbyville, Thomas J ^a,b   Gürsel, Demirkan B ^a,d   Tuskan, Robert G ^a   Walrath, Jessica C ^a   Lipschultz, Claudia A ^a   Lockett, Stephen J ^b   Wiemer, David F ^c   Beutler, John A ^a   Reilly, Karlyne M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c E11 SSH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; NATURAL PRODUCT; RHO FACTOR; SCHWEINFURTHIN A; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; CYTOSKELETON; DRUG SELECTIVITY; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NF1 GRD GENE; NONHUMAN; ONCOGENE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRP53 GENE;

ANIMALS; ANIMALS, NEWBORN; BRAIN NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GENES, NEUROFIBROMATOSIS 1; GLIOMA; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTEIN STRUCTURE, TERTIARY; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; STILBENES; SUBSTRATE SPECIFICITY;

EID: 77952151244     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0834     Document Type: Article

References (54)

1. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009;325:161-165
2. Dixon N, Wong LS, Geerlings TH, Micklefield J. Cellular targets of natural products. Nat Prod Rep 2007;24:1288-1310
3. Beutler JA, Shoemaker RH, Johnson T, Boyd MR. Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod 1998; 61:1509-1512 (Pubitemid 29024427)
4. CBTRUS. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Hinsdale (IL): Central Brain Tumor Registry of the United States; 2008.
5. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-887
6. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024
7. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
8. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321: 1807-1812
9. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-113
10. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-130 (Pubitemid 41132741)
11. Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999.
12. Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 2007;20:135-141
13. Blatt J, Jaffe R, Deutsch M, Adkins JC. Neurofibromatosis and childhood tumors. Cancer 1986;57:1225-1229
14. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986;314:1010-1015
15. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68:1110-1118
16. Serra E, Rosenbaum T, Winner U, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000;9:3055-3064
17. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 2008;135:437-448
18. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-922
19. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003;63:8573-8577
20. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286:2172-2176 (Pubitemid 129516295)
21. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004;103:4243-4250
22. Tischler A, Shih T, Williams B, Jacks T. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr Pathol 1995;6:323-335
23. Vogel K, Klesse L, Velasco-Miguel S, Meyers K, Rushing E, Parada L. Mouse tumor model for neurofibromatosis type 1. Science 1999;286: 2176-2179
24. Zhu Y, Harada T, Liu L, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005;132:5577-5588
25. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 2007;26:4609-4616
26. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001;104:593-604.
27. Martin G, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990;63:843-849
28. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-273
29. Llaguno SA, Chen J, Kwon CH, Parada LF. Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol 2008;73:421-426
30. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-715
31. Joseph NM, Mosher JT, Buchstaller J, et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008;13:129-140
32. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008;13:105-116
33. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer 2007;110:2535-2541
34. Lustig R, Mikkelsen T, Lesser G, et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro-oncol 2008;10:1004-1009
35. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507-516
36. Ozawa T, Araki N, Yunoue S, et al. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem 2005;280:39524-39533
37. Sandsmark D, Zhang H, Hegedus B, Pelletier C, Weber J, Gutmann D. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res 2007;67:4790-4799
38. Huang Y, Rangwala F, Fulkerson PC, et al. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 2004;23:368-378
39. Kim H, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 1997;17:862-872
40. Neighbors JD, Beutler JA, Wiemer DF. Synthesis of nonracemic 3-deoxyschweinfurthin B. J Org Chem 2005;70:925-931
41. Topczewski JJ, Neighbors JD, Wiemer DF. Total synthesis of (+)- schweinfurthins B and E. J Org Chem 2009;74:6965-6972
42. Mente NR. Cascade Cyclizations in Synthesis of Isoprenoid Natural Products [Ph.D Thesis]. Iowa City: University of Iowa; 2008.
43. Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Bioorg Med Chem Lett 2007;17:911-915
44. http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
45. Reilly KM, Broman KW, Bronson RT, et al. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res 2006;66:62-68
46. Hawes JJ, Nerva JD, Reilly KM. Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. J Biomol Screen 2008;13:795-803.
47. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 2001;276:7240-7245
48. http://dtp.nci.nih.gov/docs/misc/common-files/cell-list.html.
49. Salhia B, Hwang JH, Smith CA, et al. Role of myosin II activity and the regulation of myosin light chain phosphorylation in astrocytomas. Cell Motil Cytoskeleton 2008;65:12-24.
50. Dahlberg WK, Little JB, Fletcher JA, Suit HD, Okunieff P. Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol 1993; 63:191-198 (Pubitemid 23042922)
51. Mattingly RR, Kraniak JM, Dilworth JT, et al. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther 2006; 316:456-465
52. Gutmann D, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results inincreased astrocyte proliferation. Oncogene 1999;18: 4450-4459 (Pubitemid 29396653)
53. Wu M, Wallace MR, Muir D. Tumorigenic properties of neurofibromin- deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice. J Neurosci Res 2005;82:357-367 (Pubitemid 41552486)
54. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 1998;187:1893-1902